Comparison of the Ambu AuraGain and Intersurgical i-Gel Laryngeal Masks in Elective Laparoscopic Cholecystectomy
NCT ID: NCT04206592
Last Updated: 2021-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
88 participants
INTERVENTIONAL
2019-11-18
2020-03-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesise that when comparing the Ambu® AuraGainTM with Intersurgical i-GelTM mask, the Ambu® AuraGainTM would exhibit a higher oropharyngeal leak pressure (OLP) during mechanical ventilation in patients undergoing laparoscopic cholecystectomy.
The main goal is to compare the Ambu AuraGain with the i-Gel in terms of safety and efficacy during mechanical ventilation in critical phase of the pneumoperitoneum in lateral decubitus and reverse trendelemburg position. Secondary objectives are comparing insertion time, number of attempts, ventilatory airway peak pressure, time and success rates for gastric tube insertion and the incidence of side effects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AuraGainTM and I-Gel® Laryngeal Masks in General Anesthesia for Laparoscopic Cholecystectomy
NCT02925598
Ambu®AuraGain™ Versus I-gel® in Obese Patients
NCT03110393
RCT:Oropharyngeal Leak Pressure (OLP) - Ambu AuraGain vs LMA Supreme
NCT02816463
Ambu AuraGain vs LMA Supreme in Laparoscopic Surgery
NCT02511652
Comparative Evaluation of Ambu AuraGain Laryngeal Mask and Proseal Laryngeal Mask Airway
NCT03139292
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The need for orotracheal intubation during surgery will be considered as a study withdrawal criterion.
The primary outcome is the oropharyngeal leak pressure (OLP).
The secondary outcomes are: insertion time, number of attempts, ventilatory airway peak pressure, time, and success rates for gastric tube insertion and side effects.
Sample size has been calculated to detect a significant difference in oropharyngeal leak pressure (OLP) between two devices. According to the results of previous studies, the investigators assume a mean OLP of 29.2 (3.3) cmH2O for the i-Gel and of 34 (5) cmH2O for the Ambu AuraGain. In order to detect a difference of 10%, assuming a standard deviation of 5 cmH2O for both devices, 44 patients are required per group with a power of 80% and an alpha error of 0.05. To cover against a dropout rate of 10%, a total of 98 patients will be recruited.
The patients included in the study will be numbered consecutively and assigned to one of the two groups, 'LMA Ambu AuraGain' or 'i-gel', using a computer-generated random number table, by the principal investigator. The individual result will be kept in opaque envelopes. After the recruitment, the day of the procedure, the enrolling investigator will open sealed, opaque envelopes that conceal the group allocation. Participants will be blinded to their group allocation.
Procedures In the operating room, intravenous access will be secured and routine monitoring using ECG, non-invasive blood pressure, heart rate, oxygen saturation, end-tidal carbon dioxide (EtCO2) and sevoflurane (EtSevo) (Datex-Ohmeda S/5 Compact Critical Care Monitor; GE Healthcare). After pre-oxygenation with 100% oxygen by facemask for 3 min, anaesthesia will be induced with intravenous Fentanyl 50 μg/ml (2μg/kg), Propofol 1% (2-3 mg/kg) and Rocuronio 1% (0,6 mg/kg). The investigators will continue ventilating with 100% oxygen using a facemask at least for 1 min until optimum conditions for laryngeal mask insertion are achieved (loss of eyelash reflex, relaxation of the jaw, immobility, and apnoea).
Anesthesia will be maintained with Sevoflurane 2% in an air-oxygen mixture using a circle system with a fresh gas flow of 2 l/min. Additional intravenous Fentanyl will be administrated as clinically needed during anesthesia by an increase of 10-20% in blood pressure or heart rate. Laryngeal masks size will be determined according to the manufacturers weight-based recommendations and the insertion technique will be according to the recommendations of the Instruction Manual. After successful insertion, the cuff will be inflated with air until 60 cmH2O intracuff pressure (ICP) measured using an Ambu® airway pressure manometer (AMBU, S.L. B- 81040149, Alcala, Madrid, Spain). The second measurement of intracuff pressure will be performed for surgeries taking over an hour to ensure that the intracuff pressure has not changed significantly (± 5 cmH2O) since the last calibrated intracuff pressure. An effective airway will be judged by a square wave capnograph trace, bilateral chest auscultation and no audible leak with peak airway pressures at 12 cmH2O or greater during gentle manual ventilation. The device will be connected to the respiratory machine (Datex-Ohmeda S/5 Compact Critical Care Monitor; GE Healthcare) and patients will be ventilated with a tidal volume of 8 ml/kg, adjusting the respiratory rate to an end-tidal CO2 of 30-35mmHg.
A gastric tube will be inserted via the drain tube. The correct placement of the gastric tube will be confirmed by free movement during insertion and by aspiration of gastric fluid or detection of injected air by epigastric auscultation. Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 liters/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
The leak pressure will be recorded before peritoneal insufflation and during pneumoperitoneum. The peritoneal insufflation pressure will be set at 12 mmHg. At the end of the surgery, the anesthesiologist will remove the laryngeal masks when the patients obey commands. The patients will be transferred to the Post-Anaesthesia Care Unit (PACU) to be monitored after the surgery.
Statistical Analysis Data will be entered into an Excel Database. All statistical analyses will be conducted using software from the Statistical Package for the Social Sciences (SPSS, Version 18.0, Chicago, IL, USA). The distribution of data will be determined using Kolmogorov- Smirnov analysis. The quantitative variables will be summarized with means and standard deviations or with medians and percentiles P25 and P75 in case of asymmetric distributions, and qualitative variables with frequencies and percentages. To study the relationships between qualitative variables, contingency tables will be made and the Chi-square or Fisher's tests will be used. The difference in oropharyngeal leak pressure (OLP) between two devices will be analyzed by a Student ́s t-test or the Mann-Whitney U test in case of non-normal distributions. To compare the incidence of side effects between the groups, the exact Fisher test or Chi-squared tests will be used. Significant differences will be quantified with 95% confidence intervals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
i Gel LMA
The sealing pressure of the igel laryngeal mask will be measured during pneumoperitoneum in elective laparoscopic cholecystectomy
Oropharyngeal leak pressure during pneumoperitoneum.
Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
Ambu Aura Gain
It will be compared the Ambu Aura Gain LMA vs iGel in elective laparoscopic cholecystectomy
Oropharyngeal leak pressure during pneumoperitoneum.
Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oropharyngeal leak pressure during pneumoperitoneum.
Oropharyngeal Leak Pressure (OLP) will be measured by closing the expiratory valve of the circle system at a fixed gas flow of 3 litres/min (maximum allowed 40 cmH2O) recording the pressure at which equilibrium has been reached or audible air is leaking.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anaesthesiologists physical status I-III
* Elective Laparoscopic Cholecystectomy
Exclusion Criteria
* Mouth opening less than 35 mm
* Cervical spine disease
* BMI≥35 kg/m2
* Upper respiratory or digestive tract disease
* Severe obstructive pulmonary disease
* Recent history of upper respiratory tract infection
* Pregnancy
* Patients who have a risk of gastric aspiration
* Preoperative sore throat
* Patients who refuse to participate
Withdrawal criterion:
-Orotracheal intubation during surgery
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Plató
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Teresa García-Navia
Role: PRINCIPAL_INVESTIGATOR
Hospital Plato
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anesthesia Department, Hospital Plató
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MLA- Anesth
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.